Landmark Bio Unveils New State-of-the-Art Full-Spectrum Biomanufacturing Innovation Center
Landmark Bio PBLLC, a statutory public benefit limited liability company, or PBLLC, is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate the development and industrialization of novel therapeutics
– New 44,000 square-foot fully integrated facility for development, manufacturing and testing of cell and gene therapies in Watertown, Massachusetts, offers end-to-end capabilities and one-stop manufacturing solutions –
WATERTOWN, Mass., Oct. 27, 2022 /PRNewswire/ -- Landmark Bio™, a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine, today announced the opening of its state-of-the-art full-spectrum development and biomanufacturing facility in Watertown.
"Landmark Bio is a unique venture bringing together the best of academia, industry, and research hospitals to translate groundbreaking research into life-changing therapies," said Ran Zheng, chief executive officer of Landmark Bio.
"By fostering a strong cross-sector collaboration, we aim to solve three critical challenges in novel therapy development – capabilities, technology, and talent. We provide expertise in novel modality product design and development, innovative manufacturing technologies, in-house quality control capabilities, and best-in-class development, regulatory and supply chain management practices to enable fast to clinic with a line of sight to commercialization. We are grateful for the generous support of our founding partners, collaborating institutions and the life sciences community in Massachusetts as we push the frontiers of life sciences innovation to ultimately benefit patients," she added.
